- Home
- SWVL vs SNTI Comparison
SWVL vs SNTI Comparison
Compare SWVL & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWVL
- SNTI
- Stock Information
- Founded
- SWVL 2017
- SNTI 2016
- Country
- SWVL United Arab Emirates
- SNTI United States
- Employees
- SWVL N/A
- SNTI N/A
- Industry
- SWVL Business Services
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- SWVL Consumer Discretionary
- SNTI Health Care
- Exchange
- SWVL Nasdaq
- SNTI Nasdaq
- Market Cap
- SWVL 44.5M
- SNTI 44.1M
- IPO Year
- SWVL N/A
- SNTI N/A
- Fundamental
- Price
- SWVL $3.93
- SNTI $1.58
- Analyst Decision
- SWVL
- SNTI Strong Buy
- Analyst Count
- SWVL 0
- SNTI 2
- Target Price
- SWVL N/A
- SNTI $8.50
- AVG Volume (30 Days)
- SWVL 9.6K
- SNTI 451.8K
- Earning Date
- SWVL 08-19-2025
- SNTI 08-07-2025
- Dividend Yield
- SWVL N/A
- SNTI N/A
- EPS Growth
- SWVL N/A
- SNTI N/A
- EPS
- SWVL N/A
- SNTI N/A
- Revenue
- SWVL $17,207,362.00
- SNTI N/A
- Revenue This Year
- SWVL N/A
- SNTI N/A
- Revenue Next Year
- SWVL N/A
- SNTI $150.00
- P/E Ratio
- SWVL N/A
- SNTI N/A
- Revenue Growth
- SWVL N/A
- SNTI N/A
- 52 Week Low
- SWVL $2.40
- SNTI $1.51
- 52 Week High
- SWVL $7.50
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- SWVL 43.77
- SNTI 30.04
- Support Level
- SWVL $3.61
- SNTI $1.51
- Resistance Level
- SWVL $4.09
- SNTI $1.74
- Average True Range (ATR)
- SWVL 0.26
- SNTI 0.12
- MACD
- SWVL -0.01
- SNTI -0.00
- Stochastic Oscillator
- SWVL 42.95
- SNTI 11.04
About SWVL Swvl Holdings Corp
Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.